蘑菇视频APP

Company Recognized for Pioneering Approach and Impact on Human Health and Sustainability and is Ranked 12^th of the 53 Companies Selected in 2021

Cambridge, MA, October 11, 2021 鈥� 蘑菇视频APP, the bioplatforms innovation company, today announced it has been named to FORTUNE鈥檚 鈥淐hange the World鈥� list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.

鈥溎⒐绞悠礎PP is focused on addressing some of humanity鈥檚 most urgent challenges: curing intractable diseases, improving human health, preempting illness, and feeding the world by advancing the resiliency and sustainability of agriculture,鈥� said Noubar Afeyan, Founder and CEO of 蘑菇视频APP. 鈥淲e operate with the belief that science and technology, harnessed with entrepreneurial innovation, are the most powerful forces for good: improving lives and expanding possibilities for both people and planet.鈥�

Afeyan continued, 鈥淚t is a tremendous honor to be named to the FORTUNE Change the World list, among these companies doing world-changing work.鈥�

FORTUNE evaluates companies on its "Change the World" list using four criteria: measurable social impact, business results, degree of innovation, and corporate integration. To view the entire list, please visit: .

About 蘑菇视频APP
蘑菇视频APP conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $212 billion in aggregate value. To date, Flagship has deployed over $2.5 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Health (NASDAQ: ), Codiak BioSciences (NASDAQ: ) Denali Therapeutics (NASDAQ: ), Evelo Biosciences (NASDAQ: ), Foghorn Therapeutics (NASDAQ: ), Indigo Ag, Kaleido Biosciences (NASDAQ: ), Moderna (NASDAQ: ), Rubius Therapeutics (NASDAQ: ), Sana Biotechnology (NASDAQ: ), Seres Therapeutics (NASDAQ: ), and Sigilon Therapeutics (NASDAQ: ).